CANTIL
LOE ApproachingNDAORALTABLET
Approved
Nov 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CANTIL is an oral tablet small-molecule NDA approved in 1956 by Sanofi. The specific indication and mechanism of action are not currently available in the dataset. This is a legacy product nearing loss of exclusivity.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team consolidation and focus on lifecycle management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CANTIL currently has zero linked job openings, reflecting its mature, legacy status. Career opportunities on this product are limited and primarily maintenance-focused rather than growth-oriented.
Brand ManagerField Sales
Worked on CANTIL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.